1	KAMALA D. HARRIS	<i>,</i>	
2	Attorney General of California MARC D. GREENBAUM		
3	Supervising Deputy Attorney General MICHAEL A. CACCIOTTI		
4	Deputy Attorney General State Bar No. 129533	,	
5	300 So. Spring Street, Suite 1702 Los Angeles, CA 90013		
6	Telephone: (213) 897-2932 Facsimile: (213) 897-2804		
7	Attorneys for Complainant		
8	BEFORE THE BOARD OF PHARMACY DEPARTMENT OF CONSUMER AFFAIRS STATE OF CALIFORNIA		
9			
10	STATE OF		
11	In the Matter of the Accusation Against:	Case No. 5233	
12	EDIO CORP. DBA UNIVERSITY CARE PHARMACY		
13	5848 Santa Monica Blvd. Los Angeles, CA 90038	ACCUSATION	
14	Pharmacy Permit No. PHY 50352,		
15	and		
16	LISA CAROL HOLLOMAN		
17	9009 Lloyd Pl. W. Hollywood, CA 90069		
18	Pharmacist License No. RPH 47958		
19	Respondent.		
20			
21	Complainant alleges:	•	
22	<u>PARTIES</u>		
-23	1. Virginia Herold ("Complainant") brings this Accusation solely in her official capacity		
24	as the Executive Officer of the Board of Pharmacy, Department of Consumer Affairs.		
25	2. On or about September 27, 2010, the Board of Pharmacy ("Board") issued Pharmacy		
26	Permit Number PHY 50352 to Edio Corp. dba University Care Pharmacy ("Respondent		
27	Pharmacy"). The Pharmacy Permit was in full force and effect at all times relevant to the charges		
28	brought herein, expired on September 1, 2014, and has been cancelled.		
		·	
	EDIO CORP. DBA UNIVERSITY CARE PHARMA	CYand LISA CAROL HOLLOMAN ACCUSATION	

STATUTES AND REGULATIONS

- 7. Section 4013 of the Code states:
- "(a) Any facility licensed by the board shall join the board's e-mail notification list within 60 days of obtaining a license or at the time of license renewal.
- "(b) Any facility licensed by the board shall update its e-mail address with the board's e-mail notification list within 30 days of a change in the facility's e-mail address.
- "(c) An owner of two or more facilities licensed by the board may comply with subdivisions (a) and (b) by subscribing a single e-mail address to the board's e-mail notification list, where the owner maintains an electronic notice system within all of its licensed facilities that, upon receipt of an e-mail notification from the board, immediately transmits electronic notice of the same notification to all of its licensed facilities. If an owner chooses to comply with this section by using such an electronic notice system, the owner shall register the electronic notice system with the board by July 1, 2011, or within 60 days of initial licensure, whichever is later, informing the board of the single e-mail address to be utilized by the owner, describing the electronic notice system, and listing all facilities to which immediate notice will be provided. The owner shall update its e-mail address with the board's e-mail notification list within 30 days of any change in the owner's e-mail address.
 - "(d) This section shall become operative on July 1, 2010."
 - 8. Section 4081, subdivision (a) of the Code states:
- "(a) All records of manufacture and of sale, acquisition, receipt, shipment, or disposition of dangerous drugs or dangerous devices shall be at all times during business hours open to inspection by authorized officers of the law, and shall be preserved for at least three years from the date of making. A current inventory shall be kept by every manufacturer, wholesaler, third-party logistics provider, pharmacy, veterinary food-animal drug retailer, physician, dentist, podiatrist, veterinarian, laboratory, clinic, hospital, institution, or establishment holding a currently valid and unrevoked certificate, license, permit, registration, or exemption under Division 2 (commencing with Section 1200) of the Health and Safety Code or under Part 4

(commencing with Section 16000) of Division 9 of the Welfare and Institutions Code who maintains a stock of dangerous drugs or dangerous devices."

9. Section 4301 of the Code states, in pertinent part:

"The board shall take action against any holder of a license who is guilty of unprofessional conduct or whose license has been procured by fraud or misrepresentation or issued by mistake.

Unprofessional conduct shall include, but is not limited to, any of the following:

"(f) The commission of any act involving moral turpitude, dishonesty, fraud, deceit, or corruption, whether the act is committed in the course of relations as a licensee or otherwise, and whether the act is a felony or misdemeanor or not.

"(g) Knowingly making or signing any certificate or other document that falsely represents the existence or nonexistence of a state of facts.

"(j) The violation of any of the statutes of this state, or any other state, or of the United .

States regulating controlled substances and dangerous drugs.

"(o) Violating or attempting to violate, directly or indirectly, or assisting in or abetting the violation of or conspiring to violate any provision or term of this chapter or of the applicable federal and state laws and regulations governing pharmacy, including regulations established by the board or by any other state or federal regulatory agency."

10. Section 4342, subdivision (a) of the Code states:

"(a) The board may institute any action or actions as may be provided by law and that, in its discretion, are necessary, to prevent the sale of pharmaceutical preparations and drugs that do not conform to the standard and tests as to quality and strength, provided in the latest edition of the United States Pharmacopoeia or the National Formulary, or that violate any provision of the Sherman Food, Drug, and Cosmetic Law (Part 5 (commencing with Section 109875) of Division 104 of the Health and Safety Code)."

- 11. Health and Safety Code section 111335 states, "[a]ny drug or device is misbranded if its labeling or packaging does not conform to the requirements of Chapter 4 (commencing with Section 110290)."
 - 12. Health and Safety Code section 111345 states:

"Any drug or device is misbranded if any word, statement, or other information required by or under this part to appear on the label or labeling is not prominently placed on the label or labeling with conspicuousness, as compared with other words, statements, designs, or devices in the labeling, and in terms as to render it likely to be read and understood by the ordinary individual under customary conditions of purchase and use.

- 13. California Code of Regulations, title 16, section 1707.5, subdivision (d) states:
- "(d) The pharmacy shall have policies and procedures in place to help patients with limited or no English proficiency understand the information on the label as specified in subdivision (a) in the patient's language. The pharmacy's policies and procedures shall be specified in writing and shall include, at minimum, the selected means to identify the patient's language and to provide interpretive services in the patient's language. The pharmacy shall, at minimum, provide interpretive services in the patient's language, if interpretive services in such language are available, during all hours that the pharmacy is open, either in person by pharmacy staff or by use of a third-party interpretive service available by telephone at or adjacent to the pharmacy counter."

COST RECOVERY

14. Section 125.3 of the Code states, in pertinent part, that the Board may request the administrative law judge to direct a licentiate found to have committed a violation or violations of the licensing act to pay a sum not to exceed the reasonable costs of the investigation and enforcement of the case.

RELEVANT BACKGROUND FACTS

15. On January 15, 2013, the Board received a letter dated January 9, 2013 from the State of California, Department of Health Care Services contending that after conducting a field audit review of Respondent Pharmacy, the Department of Health Care Services determined that Respondent Pharmacy did not purchase enough drug inventory to sustain dispensing.

16. On October 7, 2013, a Board Inspector conducted a routine inspection of Respondent Pharmacy. Respondent Holloman was present during the inspection, as was owner Yana Zilberman, and a potential purchaser of Respondent Pharmacy. During the inspection, the Board Inspector opened one of the pharmacy drawers and Respondent Holloman shouted "That drawer is not mine. It belongs to the technicians and I got nothing to do with that." In the drawer, the Board Inspector found various medications in various containers. Some of the medications were in amber vials with handwritten labels, some of the medications were in containers with printed labels but the patients' names and had been scratched out, and some of the medications were in the original manufacture containers.

FIRST CAUSE FOR DISCIPLINE

(Billing Fraud)

17. Respondent Pharmacy and Respondent Holloman are subject to disciplinary action under Code section 4301, subdivision (f) on the grounds of unprofessional conduct in that Respondent Pharmacy and Respondent Holloman committed acts of dishonesty and fraud when the Pharmacy did not reverse insurance claims for certain Medicare Part D patients' prescriptions, which were found in a drawer during a routine inspection on October 7, 2013, as follows:

Drug Name	Quantity	Description
Benicar 20mg (RX #302732) dispensed on 09/18/13	30 tablets	Respondent Pharmacy discontinued the prescription and did not reverse the billing
Hydroxyzine 25mg (RX #296727) dispensed on 10/02/13	30 tablets	Respondent Pharmacy discontinued the prescription and did not reverse the billing
Buprenorphine/naloxone 8- 2mg (RX #293255) dispensed on 9/11/13	45 tablets	Respondent Pharmacy did not reverse the billing claim
Amlodipine/benazepril 10- 20mg (RX #302081) dispensed on 9/12/13)	29 tablets	Respondent Pharmacy did not reverse the billing claim

SECOND CAUSE FOR DISCIPLINE

(Record Keeping Violations)

18. Respondent Pharmacy and Respondent Holloman are subject to disciplinary action under Code section 4301, subdivision (o), in conjunction with Code section 4081, subdivision (a),

on the grounds of unprofessional conduct for failing to maintain a proper inventory in that on

October 7, 2013, during a routine inspection, a Board Inspector discovered the following

medications in a drawer:

Drug Name

Quantity

Benicar 20mg (RX #302732)

dispensed on 00/19/12

Drug Name	Quantity
Benicar 20mg (RX #302732)	30 tablets
dispensed on 09/18/13	
Hydroxyzine 25mg (RX	30 tablets
#296727) dispensed on	-
10/02/13	
Buprenorphine/naloxone 8-	45 tablets
2mg (RX #293255) dispensed	
on 9/11/13	
Amlodipine/benazepril 10-	29 tablets
20mg (RX #302081)	
dispensed on 9/12/13)	

These medications appeared in Respondent Pharmacy's computer system as paid by insurance and therefore would not have been included in Respondent Pharmacy's inventory of dangerous of drugs.

THIRD CAUSE FOR DISCIPLINE

(Misbranded Drugs)

19. Respondent Pharmacy and Respondent Holloman are subject to disciplinary action under Code section 4301, subdivision (j) and subdivision (o), in conjunction with Code section 4342 and Health and Safety Code sections 111335 and 111345, on the grounds of unprofessional conduct in that during a routine inspection on October 7, 2013, a Board Inspector found the following medications in a drawer in amber vials without proper labeling (i.e., missing lot numbers or expiration dates):

Drug Name and Strength	Quantity
Amlodipine/benazepril 2.5mg/10mg	30 tablets
Hyzaar 50/12/5mg	30 tablets
Actonel 5 mg	30 tablets
Seroquel XR 200 mg	70 tablets

1//

б

10 ·

FOURTH CAUSE FOR DISCIPLINE

(Knowingly Misrepresenting Documents)

- 20. Respondent Pharmacy and Respondent Holloman are subject to disciplinary action under Code section 4301, subdivision (g) on the grounds of unprofessional conduct in that during a routine inspection on October 7, 2013, Respondent Holloman knowingly misrepresented the existence of a state of facts to a Board Inspector when she falsely stated that Respondent Pharmacy had in place policies and procedures to help patients with limited or no English understand the information on the prescription medication labels. The circumstances are as follows:
- 21. During the routine inspection, the Board Inspector asked Respondent Holloman for the interpretive services policies and procedures. Respondent Holloman indicted that they existed, but she could not find them. Approximately 40 to 50 minutes later, Respondent Holloman produced policies and procedures bearing her signature and dated June 19, 2013. However the document had information printed at the top (resembling fax information) stating "10/07/2013 11:28 8187823100 Kovacs Care Pharmacy Page 01/05." White erasing tape had partially whited over some lettering and "University Care Pharmacy" was handwritten on the document. The Board Inspector asked Respondent Holloman who the policies and procedures belonged to. At first, Respondent Holloman insisted that they belonged to Respondent Pharmacy. However, she eventually admitted that the policies belonged to Kovac's Care Pharmacy (PHY 51131), that they had been faxed over that very morning, and she had written "University Care Pharmacy" on the document.

FIFTH CAUSE FOR DISCIPLINE

(Failure to Have Interpretation Procedures)

22. Respondent Pharmacy and Respondent Holloman are subject to disciplinary action under Code section 4301, subdivision (o), in conjunction with California Code of regulations, title 16, section 1707.5, subdivision (d), on the grounds of unprofessional conduct, in that during a routine inspection on October 7, 2013, Respondent Pharmacy did not have policies and

9 10

27

28

19

procedures in place to help patients with limited or no English understand the information on the prescription medication labels.

SIXTH CAUSE FOR DISCIPLINE

(Failure to Join Board's E-Mail Notification)

Respondent Pharmacy and Respondent Holloman are subject to disciplinary action 23. under Code section 4301, subdivision (o), in conjunction with Code section 4013, on the grounds of unprofessional conduct in that on October 7, 2013, during a routine inspection, Respondent Holloman admitted that Respondent Pharmacy had not joined the Board's e-mail notification list. Respondent Pharmacy was required to join the e-mail within 60 days of obtaining a license.

DISCIPLINE CONSIDERATIONS

- To determine the degree of discipline, if any, to be imposed on Respondent Pharmacy, Complainant alleges that on or about January 26, 2016, in a prior action, the Board issued Citation Number CI 2014 64013 and ordered Respondent Pharmacy to pay a \$5,000.00 fine for violating Title 21, Code of Federal Regulations, § 1305.13, subdivision (e) [Purchaser must record on Copy 3 of the DEA Form 222 the number of commercial or bulk containers furnished on each item and the dates on which the containers are received by the purchaser; and Code section 4081 subdivision (a) [Records of Dangerous Drugs and Devices Kept Open for Inspection: Maintenance of Records, Current Inventory]. That Citation is now final and is incorporated by reference as if fully set forth herein,
- To determine the degree of discipline, if any, to be imposed on Respondent Holloman, Complainant alleges that on or about January 26, 2016, in a prior action, the Board issued Citation Number CI 2014 64014 and ordered Respondent Holloman to pay a \$5,000.00 fine for violating Title 21, Code of Federal Regulations, § 1305.13, subdivision (e) [Purchaser must record on Copy 3 of the DEA Form 222 the number of commercial or bulk containers furnished on each item and the dates on which the containers are received by the purchaser]; and Code section 4081 subdivision (a) [Records of Dangerous Drugs and Devices Kept Open for Inspection; Maintenance of Records, Current Inventory]. That Citation is now final and is incorporated by reference as if fully set forth herein.